Comparison of Prognosis Between Open Pancreatic Surgery With Vein Resection and Reconstruction Versus Minimally Invasive Pancreatic Surgery With Vein Resection and Reconstruction for Pancreatic Cancer

Comparison of Prognosis Between Open Pancreatic Surgery With Vein Resection and Reconstruction Versus Minimally Invasive Pancreatic Surgery With Vein Resection and Reconstruction for Pancreatic Cancer: A Multicenter Retrospective Cohort Study

The prognostic differences between open and minimally invasive radical pancreatic surgery combined with venous resection and reconstruction remain controversial, and there is a lack of high-quality evidence-based medical evidence to support either approach. Therefore, this study intends to conduct a retrospective cohort analysis, planning to enroll pancreatic cancer patients who have undergone radical pancreatic surgery (open vs. minimally invasive) combined with venous resection and reconstruction from multiple hospitals both domestically and internationally, and to collect relevant data. The primary objective is to evaluate the differences in postoperative thrombosis and the incidence of severe complications between the two groups. Furthermore, prognostic data will be collected to assess the impact of open versus minimally invasive pancreatic surgery combined with venous resection and reconstruction on both short-term and long-term all-cause mortality in pancreatic cancer patients.

Study Overview

• Status: Completed
• Conditions: Pancreatic Tumor Patients Who Consecutively Underwent Minimally Invasive or Open Pancreatic Surgery With Venous Reconstruction

• Study Type: Observational
• Enrollment (Actual): 2451

Contacts and Locations

Study Locations

• China
  • Shaanxi
    • Xi'an, Shaanxi, China, 710061
      • The First Affiliated Hospital of Xi'an Jiaotong University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patients undergoing pancreatic surgery combined with venous resection and reconstruction.

Description

Inclusion Criteria:

• diagnosis of malignant pancreatic or periampullary lesions requiring surgical pancreatic resection; preoperative imaging confirming venous involvement; undergoing pancreatic resection with simultaneous venous resection and reconstruction; and availability of complete postoperative outcome data, including thrombosis and complication grading.

Exclusion Criteria:

• preoperative confirmation of distant metastasis.

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort
Open; The open pancreatic surgery with venous resection and reconstruction cohort
MIS; The minimally invasive pancreatic surgery with venous resection and reconstruction cohort

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
incidences of postoperative thrombosis		within 30 postoperative days
incidences of major complication	Postoperative complications were defined and graded according to the Clavien-Dindo (C-D) classification system ranging from Grade I (minor deviation) to Grade V (death), with C-D ≥III being considerated as major complication	within 30 postoperative days

Secondary Outcome Measures

Outcome Measure	Time Frame
incidence of postoperative pancreatic fistula	within 30 postoperative days
incidence of postoperative delayed gastric emptying	within 30 postoperative days
incidence of postoperative post-pancreatectomy hemorrhage	within 30 postoperative days
postoperative overall survival	before discharge, and at 3, 6, 12, 18, 24, 30, and 36 months postoperatively
postoperative recurrence-free survival	before discharge, and at 3, 6, 12, 18, 24, 30, and 36 months postoperatively

Collaborators and Investigators

• Sponsor: First Affiliated Hospital Xi'an Jiaotong University

Study record dates

Study Major Dates

• Study Start (Actual): October 1, 2024
• Primary Completion (Actual): December 31, 2024
• Study Completion (Actual): July 31, 2025

Study Registration Dates

• First Submitted: February 10, 2026
• First Submitted That Met QC Criteria: February 10, 2026
• First Posted (Actual): February 17, 2026

Study Record Updates

• Last Update Posted (Actual): February 17, 2026
• Last Update Submitted That Met QC Criteria: February 10, 2026
• Last Verified: February 1, 2026

More Information

Terms related to this study

• Other Study ID Numbers: ZXIIT2024234

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No